Published: Jun 4, 2026
Written by Klarity Editorial Team
Published: Jun 4, 2026

Finding quality mental health care has never been more important—or more complicated. The telehealth landscape has transformed dramatically over the past few years, with some providers shutting down entirely while others have emerged as trusted leaders. If you’re considering online mental health treatment for conditions like ADHD, anxiety, depression, or insomnia, understanding your options is crucial.
This comprehensive guide examines the current state of telehealth mental health services, comparing major providers, their prescribing policies, and what’s changed in the wake of recent industry upheaval.
The mental health telehealth boom of 2020-2021 promised unprecedented access to care. Platforms like Cerebral, Done, and Ahead attracted millions of patients with their promise of quick appointments and easy medication access. But by 2022, cracks began to show.
The reality check came hard and fast. Done Global, once a leading ADHD telehealth provider, saw its top executives criminally indicted in June 2024 for allegedly operating what prosecutors called a ‘subscription drug mill’ that distributed millions of Adderall prescriptions without proper evaluation. Ahead shut down completely in 2022 due to operational and financial pressures. Cerebral, after intense scrutiny over its prescribing practices, paid $3.6 million in settlements and stopped prescribing ADHD stimulants to new patients entirely.
These aren’t just corporate scandals—they represent a fundamental shift in how telehealth mental health care operates. The era of ‘easy Adderall online’ has ended, replaced by a more cautious, regulated environment that prioritizes patient safety over convenience.
For patients seeking legitimate care, this creates both challenges and opportunities. While some questionable providers have exited, quality-focused platforms have strengthened their offerings. The key is knowing which providers you can trust and what they actually offer.
One of the most significant changes in telehealth mental health care involves controlled substance prescribing. Here’s what you need to know about current policies:
The prescribing of Schedule II stimulants—the most commonly prescribed ADHD medications—has become highly restricted via telehealth. Most direct-to-consumer platforms no longer prescribe these medications at all.
Cerebral stopped all new stimulant prescriptions in May 2022 under regulatory pressure, though existing patients were grandfathered through 2023. General telehealth services like PlushCare, MDLive, Teladoc, and Amwell have policies explicitly prohibiting ADHD stimulant prescriptions.
The notable exception is Talkiatry, a psychiatry-focused platform that works within insurance networks. Their board-certified psychiatrists can prescribe stimulant medications when clinically appropriate, following thorough evaluations and ongoing monitoring.
Benzodiazepines for anxiety are similarly restricted. Nearly all telehealth platforms have adopted policies against prescribing these controlled anxiolytics. Brightside explicitly states they do not offer benzodiazepines, focusing instead on non-addictive alternatives like SSRIs. PlushCare and Teladoc maintain similar prohibitions.
This doesn’t mean anxiety can’t be treated via telehealth—it means the treatment approach emphasizes safer, non-controlled medications along with therapy.
Schedule IV ‘Z-drugs’ for insomnia face widespread restrictions. Brightside’s policy forbids Ambien and Lunesta, while Teladoc and Amwell also exclude these from their telehealth prescribing. Patients with insomnia are typically offered non-controlled alternatives like trazodone, cognitive behavioral therapy for insomnia (CBT-I), or referrals to sleep specialists.
Interestingly, while controlled substances for mental health face restrictions, GLP-1 medications for weight loss (Wegovy, Ozempic) have become widely available through telehealth. Hims & Hers launched a successful weight loss program in 2023, and PlushCare will prescribe GLP-1s for appropriate candidates with obesity or metabolic concerns.
These medications aren’t DEA-controlled, making them easier to prescribe via telehealth while still requiring proper medical evaluation.
Understanding what each platform offers—and doesn’t offer—is essential for making an informed choice. Here’s how the major players stack up:
Talkiatry represents the gold standard for comprehensive psychiatric care via telehealth. Operating in 43 states, Talkiatry employs board-certified psychiatrists who can diagnose and treat the full spectrum of mental health conditions, including prescribing controlled medications when appropriate.
The platform works within insurance networks, with typical patient costs ranging from $25-$75 copays for insured visits. Without insurance, initial evaluations cost $250-$300, with follow-ups around $150. Wait times for appointments can range from a few days to 2-3 weeks depending on your location and insurance.
Brightside takes a different approach, focusing exclusively on depression, anxiety, PTSD, OCD, and insomnia—but explicitly excluding ADHD treatment. Their psychiatrists prescribe only non-controlled medications, which appeals to patients who prefer avoiding addictive substances. Pricing runs $95/month for medication management alone or $349/month for combined therapy and medication. Brightside accepts insurance nationwide, potentially reducing out-of-pocket costs.
Teladoc, MDLive, and Amwell offer mental health care as part of broader telehealth platforms covering everything from urgent care to dermatology. All three operate nationwide and widely accept insurance, often with low copays ($0-$75).
However, their mental health prescribing is highly restricted. None prescribe ADHD stimulants, benzodiazepines, or sleep medications. They’re best suited for patients needing treatment for mild-to-moderate depression or anxiety with non-controlled medications, or those wanting the convenience of having all healthcare needs in one platform.
PlushCare focuses on primary care with mental health as a secondary offering. At $19.99/month membership plus $129 per visit, it’s affordable for straightforward medical needs. PlushCare can prescribe GLP-1 weight loss medications, making it useful for patients addressing both metabolic and mental health concerns. However, like other general platforms, controlled psychiatric medications are off the table.
Hims & Hers has carved out a niche in lifestyle wellness, including anxiety and depression treatment alongside hair loss, sexual health, and weight management. Their mental health services cost $85/month for medication management, with therapy available at $99/session. Notably, Hims offers GLP-1 weight loss programs, positioning itself as a comprehensive wellness solution.
The platform doesn’t prescribe controlled substances, limiting its usefulness for ADHD or complex anxiety disorders. However, for patients dealing with mild-to-moderate depression or anxiety alongside other wellness goals, the integrated approach can be appealing.
Cerebral continues to operate but in a dramatically reduced capacity after its 2022 controversies. While still treating depression, anxiety, and existing ADHD patients (with non-stimulant alternatives), it stopped all new stimulant prescriptions. Subscription costs range from $99-$365/month depending on services. Patient reviews have been mixed, with common complaints about provider turnover and customer service responsiveness.
Done is effectively defunct following the June 2024 indictment of its executives. Though the website technically remains live, the company cannot operate as a functional healthcare provider. Patients who were using Done for ADHD treatment have had to scramble to find new providers—a significant disruption that highlights the risks of relying on platforms that cut corners.
Ahead shut down completely in 2022, leaving patients without warning and forcing them to transfer care elsewhere.
Most major telehealth platforms now operate nationwide, but there are important nuances:
Nationwide Coverage (50 States):
Limited State Coverage:
For residents of California, Texas, Florida, New York, Pennsylvania, and Illinois—the most populous states—all actively operating platforms are available. However, specific services within those states may vary based on local regulations around controlled substance prescribing and insurance network participation.
Telehealth mental health pricing varies dramatically based on the platform, services needed, and whether you use insurance:
These models provide predictable costs but can be expensive if you don’t need frequent appointments. Patients often complain about difficulty canceling subscriptions or being charged for months when they don’t actually see a provider.
Pay-per-visit models offer more flexibility, especially for patients who don’t need monthly appointments. However, costs can add up quickly without insurance.
Insurance acceptance makes a significant difference in affordability:
Widely Insurance-Accepted:
Limited or No Insurance:
For insured patients, platforms like Talkiatry often provide the best value—comprehensive psychiatric care at specialist copay rates ($25-$75). For uninsured patients or those with high deductibles, comparing subscription vs. pay-per-visit models is crucial.
Given this complex landscape, Klarity Health offers a compelling alternative that addresses many gaps left by other providers.
Unlike general telehealth platforms that refuse to prescribe controlled medications, Klarity provides comprehensive psychiatric care including ADHD treatment when medically appropriate. This puts Klarity in line with specialty platforms like Talkiatry but with greater scheduling flexibility and transparent pricing.
Klarity’s pricing structure—typically around $149 for initial evaluations and $59 for follow-ups—offers significant savings compared to subscription-based competitors like Cerebral ($99-$365/month) or Brightside ($349/month for combined services). For patients needing monthly medication management, Klarity’s approach costs roughly $700-$850 annually compared to $1,188-$4,380 for subscription platforms.
Availability is another advantage. Klarity operates in multiple states with licensed providers who can prescribe the full range of psychiatric medications, including controlled substances when clinically indicated. This fills the void left by Done’s collapse and Ahead’s shutdown—providing legitimate ADHD care without the reckless prescribing practices that led to their downfall.
The platform accepts both insurance and cash pay, offering flexibility that subscription-only services lack. Patients can use insurance benefits when available or pay transparent self-pay rates without surprise bills or membership fees.
Perhaps most importantly, Klarity emphasizes continuity of care. You see the same provider for follow-up visits rather than whoever’s available, building the therapeutic relationship essential for effective mental health treatment. This contrasts with some larger platforms where patients complain about constant provider changes.
Before selecting a platform, ask yourself these key questions:
What conditions do you need treated?
What’s your budget and insurance situation?
How quickly do you need care?
What level of prescribing flexibility do you need?
The future of telehealth mental health prescribing remains somewhat uncertain. The Ryan Haight Act waiver—which allowed tele-prescribing of controlled substances during COVID—has been extended through December 2025, but its future beyond that is unclear.
The DEA and medical boards continue evaluating whether telehealth providers should be required to conduct at least one in-person exam before prescribing controlled medications. This could significantly impact access to ADHD and anxiety medications via telehealth.
What this means for patients:
The Done Global indictment sent a clear message: aggressive, corner-cutting prescribing practices will face legal consequences. Platforms that prioritize proper evaluation, documentation, and ongoing monitoring—like Talkiatry and Klarity—are positioned to thrive regardless of regulatory changes.
Recent telehealth controversies have taught important lessons. Avoid providers that:
Here’s a decision framework based on common scenarios:
Scenario 1: You need ADHD treatment with stimulant medication
Scenario 2: You have depression or anxiety and want to avoid controlled medications
Scenario 3: You want comprehensive wellness care (mental health + weight management or other concerns)
Scenario 4: You’re uninsured or have a high deductible
Scenario 5: You want the security of in-network insurance coverage
The telehealth mental health industry has matured significantly since its pandemic boom. The fly-by-night operations and questionable prescribing practices have largely been weeded out, leaving providers that prioritize legitimate care.
For patients, this means more careful evaluation of options but also greater confidence in the platforms that remain. Whether you choose an insurance-based psychiatry service like Talkiatry, a focused platform like Brightside, or a flexible option like Klarity Health, the key is matching the service to your specific needs and circumstances.
Klarity Health stands out by offering what many patients actually want: legitimate psychiatric care including controlled medications when appropriate, transparent pricing, fast appointment availability, and the flexibility to pay with insurance or out-of-pocket. This balanced approach—neither refusing to prescribe necessary medications (like general telehealth) nor over-prescribing them (like the defunct Done)—represents the future of responsible telehealth mental health care.
Ready to start your mental health journey with a provider you can trust? Klarity Health offers same-week appointments with licensed psychiatric providers who can diagnose and treat ADHD, anxiety, depression, insomnia, and other conditions—with transparent pricing starting at $149 for comprehensive initial evaluations. Get started with Klarity today and experience the difference that specialized, patient-centered care makes.
AP News – DOJ indictment of Done Global (ADHD telehealth). (Jun 14, 2024). https://apnews.com/article/498cb907623565ee680b33b1367efb84
TIME Magazine – ‘Why Online Therapy Startups Are Falling Short.’ (Nov 1, 2022). https://time.com/6225361/telehealth-startups-cerebral-done-ahead/
TechTarget – Cerebral settles over prescribing practices. (Nov 6, 2024). https://www.techtarget.com/virtualhealthcare/news/366615298/Pushing-ADHD-telehealth-prescriptions-costs-Cerebral-millions
Teladoc Health – Prescription policy FAQ. (Updated 2023). https://www.teladochealth.com/info/prescription-policy
PlushCare – Controlled substances policy FAQ. (Updated 2025). https://plushcare.com/controlled-substances-policy/
Research Currency Statement
Verified as of: January 4, 2026
Providers verified active: Cerebral, Brightside, Talkiatry, PlushCare, MDLive, Teladoc, Amwell, Hims/Hers
Providers with uncertain status: Done (legal issues; CEO/President indicted 2024), Ahead (shut down in 2022)
Key sources checked: 2024 DOJ press releases; 2025 industry news (TechTarget, AP); official provider policies (Teladoc, PlushCare, Brightside); competitor reviews and recent analyses (2025)
Find the right provider for your needs — select your state to find expert care near you.